State Street SPDR S&P Biotech ETF
314 hedge funds and large institutions have $3.6B invested in State Street SPDR S&P Biotech ETF in 2017 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 116 increasing their positions, 76 reducing their positions, and 34 closing their positions.
76% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 34
53% more repeat investments, than reductions
Existing positions increased: 116 | Existing positions reduced: 76
25% more funds holding in top 10
Funds holding in top 10: 12 → 15 (+3)
16% more capital invested
Capital invested by funds: $3.09B → $3.6B (+$510M)
8% more funds holding
Funds holding: 292 → 314 (+22)
1.67% less ownership
Funds ownership: 97.98% → 96.31% (-1.7%)
42% less call options, than puts
Call options by funds: $828M | Put options by funds: $1.43B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$135M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$113M |
| 3 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
+$89.1M |
| 4 |
Morgan Stanley
New York
|
+$62.2M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$140M |
| 2 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$105M |
| 3 |
AssetMark Inc
Concord,
California
|
-$42.6M |
| 4 |
JP Morgan Chase
New York
|
-$24.6M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$23.2M |
XBI Hedge Fund Activity: Q2 2017 in Review
314 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q2 2017, worth a combined $3.6B — up 16% from $3.09B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new XBI positions and 34 closed out — a net gain of 26 holders — while 116 added to existing stakes and 76 trimmed.
The largest buyer was Citigroup, adding an estimated $135M. The largest seller was UBS Group, cutting an estimated $140M.
- 314 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q2 2017, up from 292 in Q1 2017.
- Funds reported $3.6B of State Street SPDR S&P Biotech ETF stock for Q2 2017, up 16% quarter-over-quarter.
- 60 funds opened new State Street SPDR S&P Biotech ETF positions in Q2 2017 and 34 closed out, a net change of +26 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q2 2017 was Citigroup, an estimated $135M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q2 2017 was UBS Group, an estimated $140M sold.
Based on aggregated 13F filings for Q2 2017.